Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NBTX 
Nanobiotix (NBTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: NBTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.65
1 Year Target Price $7.65
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2.44% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 224.31M USD | Price to earnings Ratio - | 1Y Target Price 7.65 |
Price to earnings Ratio - | 1Y Target Price 7.65 | ||
Volume (30-day avg) 4 | Beta 1.56 | 52 Weeks Range 2.76 - 6.00 | Updated Date 06/30/2025 |
52 Weeks Range 2.76 - 6.00 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) 271.42% |
Management Effectiveness
Return on Assets (TTM) -52.89% | Return on Equity (TTM) -198.69% |
Valuation
Trailing PE - | Forward PE 48.31 | Enterprise Value 222221669 | Price to Sales(TTM) 3.82 |
Enterprise Value 222221669 | Price to Sales(TTM) 3.82 | ||
Enterprise Value to Revenue 3.39 | Enterprise Value to EBITDA -2.45 | Shares Outstanding 47404700 | Shares Floating 20590720 |
Shares Outstanding 47404700 | Shares Floating 20590720 | ||
Percent Insiders - | Percent Institutions 12.15 |
Analyst Ratings
Rating 2 | Target Price 7.65 | Buy - | Strong Buy 3 |
Buy - | Strong Buy 3 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Nanobiotix
Company Overview
History and Background
Nanobiotix was founded in 2003. It is a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for millions of cancer patients. Key milestones include advancing NBTXR3 through clinical trials and securing regulatory approvals.
Core Business Areas
- Nano-Oncology: Developing and commercializing NanoXray-activated radioenhancers like NBTXR3 to improve radiotherapy efficacy for various cancer types.
Leadership and Structure
The company is led by Laurent Levy (CEO) and has a board of directors overseeing its operations and strategy.
Top Products and Market Share
Key Offerings
- NBTXR3: NBTXR3 is Nanobiotix's lead product, a nano-sized radioenhancer designed to boost the effectiveness of radiotherapy. Market share is developing, pending further approvals and commercialization. Competitors include companies developing alternative radiotherapy enhancers or novel radiation delivery methods. Detailed market share data specific to NBTXR3 is still nascent as it navigates commercialization.
Market Dynamics
Industry Overview
The oncology therapeutics market is experiencing significant growth, driven by increasing cancer incidence and advancements in treatment modalities.
Positioning
Nanobiotix aims to disrupt traditional cancer treatment paradigms by enhancing radiotherapy, offering a potential advantage in certain tumor types.
Total Addressable Market (TAM)
The TAM for radiotherapy enhancement is substantial, projected to be in the billions of dollars. Nanobiotix is positioning itself to capture a portion of this market by improving treatment outcomes and patient quality of life.
Upturn SWOT Analysis
Strengths
- Novel technology platform
- Positive clinical trial results for NBTXR3
- Experienced management team
- Strategic partnerships
Weaknesses
- Limited commercialization experience
- High R&D expenses
- Dependence on a single lead product
- Requires significant capital
Opportunities
- Expanding NBTXR3 indications
- Entering new geographic markets
- Developing new products based on NanoXray technology
- Partnerships with pharmaceutical companies
Threats
- Regulatory hurdles
- Competition from established cancer therapies
- Clinical trial failures
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- VAR
- Varian Medical Systems (Siemens)
- EBT
Competitive Landscape
Nanobiotix faces competition from established radiotherapy equipment manufacturers and companies developing alternative cancer therapies. Its advantage lies in its novel NanoXray technology and potential to improve radiotherapy efficacy.
Growth Trajectory and Initiatives
Historical Growth: Nanobiotix's growth has been driven by clinical trial progress and regulatory milestones.
Future Projections: Future growth is dependent on successful commercialization of NBTXR3 and expansion into new indications.
Recent Initiatives: Recent initiatives include securing regulatory approvals, initiating new clinical trials, and strengthening strategic partnerships.
Summary
Nanobiotix is a biotechnology company with a novel approach to cancer treatment. Its lead product, NBTXR3, has shown promise in clinical trials and regulatory hurdles could be a potential threat. Securing partnerships and expanding into new markets will be crucial for the company's future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Press releases
- Analyst reports
- SEC filings
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Market share estimates may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nanobiotix
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-12-11 | Co-Founder, President of the Executive Board & CEO Mr. Laurent Levy Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 108 | Website https://www.nanobiotix.com |
Full time employees 108 | Website https://www.nanobiotix.com | ||
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.